These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16912890)

  • 1. Risk-sharing agreements for innovative drugs: a new solution to old problems?
    de Pouvourville G
    Eur J Health Econ; 2006 Sep; 7(3):155-7. PubMed ID: 16912890
    [No Abstract]   [Full Text] [Related]  

  • 2. [Innovative agreements with the pharmaceutical industry: "pay for performance"].
    Badia X; Prior M
    Farm Hosp; 2010; 34(2):53-5. PubMed ID: 20207566
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel.
    Triki N; Ash N; Porath A; Birnbaum Y; Greenberg D; Hammerman A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):749-753. PubMed ID: 31825682
    [No Abstract]   [Full Text] [Related]  

  • 4. Italian risk-sharing agreements on drugs: are they worthwhile?
    Garattini L; Curto A; van de Vooren K
    Eur J Health Econ; 2015 Jan; 16(1):1-3. PubMed ID: 24728513
    [No Abstract]   [Full Text] [Related]  

  • 5. [Co-pay reduced--free cards for doctor hopping patients].
    MMW Fortschr Med; 2004 Feb; 146(7):54. PubMed ID: 15347052
    [No Abstract]   [Full Text] [Related]  

  • 6. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
    Hammerman A; Greenberg D
    Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of two pharmaceutical risk-sharing agreements on pricing, promotion, and net health benefits.
    Zaric GS; Xie B
    Value Health; 2009; 12(5):838-45. PubMed ID: 19490563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk sharing agreements: what lessons from Italy?
    Garattini L; Casadei G
    Int J Technol Assess Health Care; 2011 Apr; 27(2):169-72. PubMed ID: 21429288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry.
    Barros PP
    Health Econ; 2011 Apr; 20(4):461-70. PubMed ID: 21394816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drugs: money-back guarantee?].
    Steenhoek A; Koopmanschap MA; Franken MG; Rutten FF
    Ned Tijdschr Geneeskd; 2011; 155():A2042. PubMed ID: 21262015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Financial risk-sharing in updating the National List of Health Services in Israel: stakeholders' perceived interests.
    Hammerman A; Feder-Bubis P; Greenberg D
    Value Health; 2012; 15(5):737-42. PubMed ID: 22867784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Social security recipients: must they pay now or not?].
    MMW Fortschr Med; 2004 Feb; 146(7):56. PubMed ID: 15347055
    [No Abstract]   [Full Text] [Related]  

  • 13. Deal watch: Harnessing creative risk sharing.
    Papp T
    Nat Rev Drug Discov; 2010 Sep; 9(9):671. PubMed ID: 20811371
    [No Abstract]   [Full Text] [Related]  

  • 14. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.
    Garrison LP; Carlson JJ; Bajaj PS; Towse A; Neumann PJ; Sullivan SD; Westrich K; Dubois RW
    Am J Manag Care; 2015 Sep; 21(9):632-40. PubMed ID: 26618366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PHARMAC responds to Richard Milne on discounting health benefits and costs.
    Metcalfe S; Brougham M; Moodie P; Grocott R
    N Z Med J; 2005 Jul; 118(1219):U1600. PubMed ID: 16059415
    [No Abstract]   [Full Text] [Related]  

  • 17. Comment on "Where's the value in health care"?
    Lungen M; Gerber A
    Value Health; 2007; 10(2):170; author reply 171. PubMed ID: 17391426
    [No Abstract]   [Full Text] [Related]  

  • 18. The current performance-linked and risk sharing agreement scene in the Spanish region of Catalonia.
    Darbà J; Ascanio M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):743-748. PubMed ID: 30821532
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement.
    Neumann PJ; Chambers JD; Simon F; Meckley LM
    Health Aff (Millwood); 2011 Dec; 30(12):2329-37. PubMed ID: 22147861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health Canada proposes new regulatory regime for drugs.
    Kondro W
    CMAJ; 2007 Apr; 176(9):1261-2. PubMed ID: 17452653
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.